Navigation Links
Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Date:8/28/2007

SEATTLE, Aug. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had received a Deficiency Letter (the "Letter") from Nasdaq indicating that the Company's recently completed registered offering of Series C 3% Convertible Preferred Stock (the "Series C Preferred") and warrants did not comply with voting rights requirements set forth in Nasdaq Marketplace Rule 4351 and IM 4351. The Nasdaq staff verbally notified the Company of such noncompliance on August 9, 2007 and, in response to this verbal notification, the Company took action to cure the deficiency by amending the Articles of Amendment of the Company's Articles of Incorporation, which set forth the rights and preferences of the holders of the Series C Preferred (the "Articles of Amendment"). The amendment to the Articles of Amendment (the "Amendment") adjusted the conversion ratio of the Series C Preferred for purposes of the voting rights provision of the Articles of Amendment, and had the effect of reducing the number of votes that the holders of the Series C Preferred have because it increased the conversion price from $3.90 to $4.53 for purposes of the voting rights provision. The Amendment did not change the conversion price in any other provision of the Articles of Amendment, including but not limited to the provision on conversion of such Series C Preferred into shares of common stock.

The letter confirms that, subject to the public announcement requirements of Nasdaq Marketplace Rule 4803(a), the Company has regained compliance with Nasdaq Marketplace Rule 4351 and IM 4351 and the matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Milwaukee takes another step in electronic patient data exchange
3. Ethics Board site offers welcome contrast to state IT mistakes
4. It takes more than money to reach the top
5. CATI takes tech transfer model national
6. Green economic plan takes cue from Indiana
7. Local software company takes Google to court over a patent
8. American Family CIO takes entrepreneurial approach to innovation
9. TDS takes top spot in region in customer satisfaction rankings
10. Innovative health care takes more than just IT automation
11. Centralization mania takes over
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , 26. mája 2015 ... mene svojej rodiny prezidentom Barackovi Obamovi a Billovi ... súvislosti so stratou Dr. Rongxiang Xu , ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol pionier, ... a jeho odhodlanie v oblasti vedy a príkladné ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that all outstanding ... were exercised prior to their expiry on June 15, ... $11.7 million. "We thank our shareholders for ... and CEO of Asterias. "This exercise of warrants represents ...
(Date:5/26/2015)... Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today announced ... its Board of Directors.  His appointment strengthens Fluorinov,s leadership ... accelerates its clinical development activities.  "On ... to welcome Luke to the Board of Directors.  Luke ... strength and success of multiple organizations," said Malik ...
(Date:5/26/2015)... , May 26, 2015 US-Australian drug discovery and development ... it will present at the 2015 Marcum MicroCap Conference ... at the Grand Hyatt Hotel. The ... CEO, is scheduled to begin at 9.30 a.m. ET and will ... to http://wsw.com/webcast/marcum3/nvgn . The annual Marcum MicroCap ...
Breaking Biology Technology:Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4
... Pivotal Study in, Rituximab Refractory Follicular Non-Hodgkin,s lymphoma ... Number ... Genmab A/S (OMX:,GEN) announced today it has amended the design ... follicular,non-Hodgkin,s lymphoma (NHL) to a single arm trial that will ...
... May Help Increase Appropriate Early Use in Acute Coronary Syndrome ... ... 27 ,Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb,Company (NYSE: ... approved a supplemental new drug application,(sNDA) for a 300mg tablet of the ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... data from,preclinical studies of ANX-514 (docetaxel emulsion) ... Cancer Research (AACR), National Cancer,Institute (NCI) and ...
Cached Biology Technology:Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 4FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 5ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... that fish tend to return to the same river where ... State University have determined that the old rule doesn,t always ... Using a statistical analysis of chemicals found in walleye ear ... walleye hatched in the Sandusky and Maumee rivers that returned ...
... scientist has discovered what could be the world,s rarest coral ... elkhorn coral was found while conducting underwater surveys of Arno ... Richards of the ARC Centre of Excellence for Coral Reef ... to the critically endangered and fast-vanishing elkhorn coral ( Acropora ...
... in the 29 July issue of the international journal ... algae known as "phytoplankton" have been declining globally over the ... chain and sustains diverse assemblages of species ranging from tiny ... author Daniel Boyce, "Phytoplankton is the fuel on which marine ...
Cached Biology News:Ear bones reveal spawning secrets of Lake Erie walleye 2Ear bones reveal spawning secrets of Lake Erie walleye 3Ear bones reveal spawning secrets of Lake Erie walleye 4Super-rare 'elkhorn' coral found in Pacific 2Super-rare 'elkhorn' coral found in Pacific 3New study reveals decline of marine phytoplankton over the past century 2
... Collect eliminates manual data entry by ... into any Windows-based application. Collect is ... countless hours of tedious data entry. ... balances, scales, pH meters, spectrophotometers, force gauges, ...
... autofluorescent pigment lipofuscin accumulates in the ... neurons. The presence of lipofuscin granules ... microscopy in the central nervous system ... emission spectra, which overlaps with those ...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Polyclonal Antibody to Golgin-67...
Biology Products: